Predictive Value of Pulmonary Valve Annulus Z-Score for Valve Sparing in Tetralogy of Fallot Repair: A Systematic Review and Meta-Analysis

Dicky Fakhri[1], Johan S. Sitanggang[2], Salomo Purba[1], Pribadi W. Busro[1], Budi Rahmat[1], Panji Utomo[1], Latifa Hernisa[1], Marshal B. Djaka[2], Doddy P. Pohan[2], Noverita S. Vinolina[3]

1. Division of Pediatric and Congenital Heart Surgery, Department of Thoracic, Cardiac, and Vascular Surgery, National Cardiovascular Centre of Harapan Kita, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
2. Division of Thoracic, Cardiac, and Vascular Surgery, Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
3. Department of Statistics, Universitas Sumatera Utara, Medan, Indonesia.

Corresponding author: Dicky Fakhri (difawi@yahoo.com).

Abstract

Background/Objectives: Tetralogy of Fallot (ToF) is the most prevalent cyanotic con-genital heart defect, requiring timely surgical intervention to improve survival. Two primary techniques for right ventricular outflow tract (RVOT) reconstruction are transannular patch (TAP) repair and valve-sparing (VS) surgery as a less invasive al-ternative. While TAP resolves pulmonary stenosis, it often results in long-term pul-monary regurgitation (PR). This meta-analysis investigates the pulmonary valve an-nulus (PVA) z-score as a predictor for choosing VS techniques to minimize complica-tions, mean difference and cut-off analysis.

Methods: A systematic review and me-ta-analysis were conducted across 29 studies (N=5,806) assessing preoperative PVA z-scores in patients undergoing TAP or VS RVOT reconstruction. Data extraction fol-lowed PRISMA guidelines, with statistical analyses using a random-effects model by Review Manager 5.4.1 and receiver operating characteristic (ROC) curve evaluation.

Results: The meta-analysis showed significantly higher preoperative PVA z-scores in the VS group (MD: 1.01, 95% CI: 0.75–1.28, $p < 0.001$). The pooled grand mean PVA z-scores were -1.39 for VS and -2.97 for TAP. ROC analysis identified a z-score thresh-old of ≥ -2.59 (sensitivity: 88%, specificity: 80%) as optimal for maximizing VS surgery.

Conclusions: This study establishes the PVA z-score as a potential predictor for VS approaches in ToF repair, with a proposed threshold of ≥ -2.59 for optimal outcomes. Adoption of VS techniques guided by standardized z-score criteria may

reduce PR-associated complications and enhance long-term survival and quality of life.

Keywords: *Tetralogy of Fallot, Pulmonary Valve Annulus, Z-Score, Valve-Sparing Repair, Transannular Patch, Meta-Analysis*

1. Introduction

Tetralogy of Fallot (ToF), the most prevalent cyanotic congenital heart disease (CHD), occurs in approximately 3.4 per 10,000 live births, accounting for 5% to 7% of all congenital heart anomalies. [1–3] Without prompt surgical intervention, the prognosis is poor, with only 10% of affected individuals surviving beyond 20 years of age, while the majority succumb to complications such as secondary myocardial hypertro-phy and heart failure due to prolonged hypoxia. The preferred treatment strategy involves primary repair within the first year of life, with definitive corrective surgery being the optimal approach. The hallmark features of ToF include right ventricular outflow tract (RVOT) obstruction, ventricular septal defect, overriding of the aorta, and right ventricular hypertrophy. [4,5]

Complete surgical repair of Tetralogy of Fallot (ToF) has become standard prac-tice during infancy, achieving an impressive post-repair survival rate of 95%-98% into adulthood. However, the timing of intervention and choice of surgical techniques can have profound and enduring effects on the need for future reinterventions, overall quality of life, and long-term survival of ToF patients.2 Reconstruction of the RVOT can be performed using either transannular patch (TAP) repair or valve-sparing (VS) approaches. Despite these advancements, ongoing debates persist regarding the optimal method of RVOT reconstruction, particularly in tailoring approaches to the sever-ity of the disease in individual patients. [5–7]

The pulmonary valve annulus (PVA) z-score is widely utilized as a key predictor for determining the need for TAP repair, although cutoff values vary globally due to differences in surgical preferences and institutional practices. When the PVA z-score is critically low, TAP repair is typically employed. However, a significant drawback of TAP is the disruption of pulmonary valve integrity, leading to progressive pulmonary regurgitation (PR). Minimizing the risk of postoperative

PR during initial repair is essential, as a substantial proportion of repaired ToF patients may require late pulmonary valve replacement to address complications such as right ventricular dilatation, ventricular arrhythmias, and sudden death. [5,8–10]

To mitigate the long-term sequelae of PR and the need for reoperations, contem-porary surgical approaches emphasize pulmonary valve preservation or valve-sparing (VS) techniques as a less invasive approach during primary ToF repair. Although VS strategies have evolved significantly, they are associated with a trade-off: several studies show higher risk of residual pulmonary stenosis (PS) in the early postoperative but a reduced incidence of PR. [9–12]

This meta-analysis aims to consolidate institutional experiences worldwide into a unified study, enabling the development of a more accurate preoperative cut-off value for the PVA z-score as a less invasive approach. By synthesizing data from various centers, this approach seeks to establish a standardized predictive threshold that can guide surgical decision-making. The goal is to minimize complications associated with different operative techniques by leveraging the collective expertise and outcomes re-ported across institutions over recent years.

2. Materials and Methods

A systematic review and meta-analysis was rigorously undertaken to precisely evaluate the role of the PVA z-score within the context of preoperative assessment for surgical intervention, specifically focusing on valve-sparing procedures and techniques employing transannular patch reconstruction. The comprehensive literature search was executed over a defined period, commencing in February 2025 and con-cluding in October 2025, with the final update and data extraction performed on October 31, 2025. This entire process strictly adhered to the methodological standards and reporting architecture stipulated by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

2.1. Eligibility Criteria

Studies were included in this systematic review if they met the following inclusion criteria:

1. Original research comparing VS and TAP techniques on RVOT ToF reconstruction including: randomized controlled trials or observational studies (retrospective and prospective cohort studies).
2. Relevance to the clinical PICO framework:
   - Patients: Pediatric patients (age < 18 years old) diagnosed with Tetralogy of Fallot, eligible for primary corrective treatment.
   - Intervention: Assessment of preoperative Z-scores in patients undergoing valve/annular-sparing (VS) RVOT reconstruction. VS procedure defined as any surgical reconstruction of the RVOT where the native pulmonary valve annulus is preserved (left intact). This category may includes techniques such as pulmonary valvotomy, commissurotomy, leaflet delamination, and infundibular patching (transatrial or transventricular) that terminates proximal to the pulmonary annulus.
   - Comparison: Preoperative Z-scores in patients undergoing transannular patch (TAP) RVOT reconstruction. TAP procedure included any surgical reconstruction involving an incision across the pulmonary valve annulus to relieve stenosis, typically augmented with a patch. Techniques involving annular division and patch, even if accompanied by leaflet preservation strategies, were classified as TAP for the purpose of this analysis, as they involve the disruption of the native annular valve geometry.
   - Outcome: Evaluation of the preoperative mean difference, grand means, and the cut-off value of the pulmonary valve annulus z-score for each surgical approach.

Meanwhile, several exclusion criteria were as follows:

1. Uncontrolled studies, such as descriptive studies, case series or case reports.
2. Publications not categorized as original research, including review articles or commentaries.
3. Studies with full-text articles not available in English, resulting in a language barrier.

2.2. Search and Selection for Studies

A systematic literature search was conducted across multiple databases, includ-ing PubMed, ScienceDirect, SpringerLink, Scopus, Central/Cochrane, and Google Scholar. Several records also were identified from other methods such as, websites and citations searching. The search strategy employed the following terms: ("tetralogy of Fallot" OR "ToF") AND ("valve sparing" OR "valve-sparing" OR "annulus sparing") OR (“trans annular patch” OR "transannular patch" OR "TAP") AND "z-score". Duplicate entries were excluded, and the remaining articles were independently screened for relevance based on their abstracts by six authors (DF, JS, SP, PB, BR, PU). Full-text reviews of the shortlisted articles were then conducted by the other five authors (LH, MD, DP, NV), applying the predefined inclusion and exclusion criteria.

2.3. Extraction and Quality Assesment of Data

Data extraction was independently carried out by three authors (JS, SP, DF) using standardized forms. The extracted information included the author, year of publication, study design, sample size, participant age, weight, and PVA z-score. The primary variable analyzed in the meta-analysis was the preoperative PVA z-score, reported as the mean ± standard deviation (SD), for both patient groups undergoing VS and TAP RVOT reconstruction. The PVA z-score is defined as a standardized metric quantifying the deviation of the pulmonary annulus diameter from the mean of a healthy population, normalized for body surface area, weight, and age. [12]

The quality assessment of the included observational cohort studies was inde-pendently conducted by three authors (MD, DP, NV) using the Newcastle-Ottawa Scale (NOS). This tool evaluates studies based on three broad perspectives: the selec-tion of the study groups, the comparability of the groups, and the ascertainment of the outcome of interest. Studies were awarded stars to assess quality, with a maximum possible score of 9. The results of the quality appraisal were summarized in tables, classifying studies as having good, fair, or poor quality based on their total scores. Pub-lication bias was also assessed visually by inspecting the funnel plot for asymmetry. To statistically quantify this assessment,

Egger's linear regression test was performed. A p-value of < 0.05 was considered indicative of significant publication bias.

2.4. Statistical Analysis

The statistical analysis for this study was conducted using meta-analytic methods implemented in Review Manager (RevMan) version 5.4.1. The effect estimate was expressed as the mean difference (MD) in forest plot with its standard deviation (SD) and 95% confidence interval (CI). Heterogeneity among studies in meta-analysis was evaluated using the I^2 statistic, with threshold of >50% indicating significant heterogeneity, requiring a random-effect model. A fixed-effect model was employed when heterogeneity was low. Continuous variables were analyzed using the in-verse-variance method. Statistical significance was determined using a two-tailed p-value, with a threshold of ≤ 0.05.

When data were reported as medians and interquartile ranges (IQRs), they were converted to means and standard deviations using the formula proposed by Wan et al. [13] These mean values from the meta-analysis were subsequently used to construct receiver operating characteristic (ROC) curves in SPSS version 27. The area under the curve (AUC) was calculated to assess the discriminatory power of significant parame-ters, and optimal cut-off values were determined based on the sensitivity and specific-ity at various thresholds. [14]

3. Results

3.1. Literature Search and Selection

A systematic search of electronic databases and supplementary sources yielded a total of 766 records. Following the removal of 325 duplicates, 429 records remained for title and abstract screening via databases. This initial screening led to the exclusion of 318 records. We subsequently attempted to retrieve the full text of the remaining 123 reports from databases and other methods; 48 were not available, leaving 75 articles for full eligibility assessment. During this phase, 41 studies were excluded, primarily because they failed to present preoperative z-score values in patients undergoing RVOT reconstruction or lacked a direct comparison between

VS and TAP group. Ultimately, 34 studies were incorporated into the systematic review, 29 of which were in-cluded in the meta-analysis. The detailed process of the literature search and study selection is illustrated in **Figure 1.**



Figure 1. PRISMA 2020 flow diagram detailing the literature search and selection strategy.

3.2. Study Quality Assessment

The methodological quality of the 34 included studies was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies. Total quality scores ranged from 5 to 9 stars. Based on the established criteria, the majority of the studies (n = 22) were classified as good quality with a low risk of bias (scores of 7-9). The remaining 12 stud-ies were categorized as fair quality with a moderate risk of bias, scoring between 5 and 6 stars. No studies were identified as having a high risk of bias (poor quality). Sum-mary table detailing the assessment is presented in **Table A1.**

3.3. Characteristics of Studies

A total of 34 studies meeting the inclusion criteria were identified, then 29 of which included in numerical analysis comprising data from 5,806 patients with ToF. [3,5,7–12,15–40] Among these, 3,392 patients underwent RVOT reconstruction with VS, while 2,414 underwent TAP. Regarding study design, 31 studies (91.2%) were ret-rospective cohort studies, and 3 studies (8.8%) were prospective cohort

studies. This systematic review encompasses data from three continents, with 17 studies originating from Asia (50%), 10 from North America (29.4%), and 7 from Europe (20.6%). Detailed study characteristics are presented in **Table 1.**

Table 1. Characteristics of included studies.

No.	Study	Year	Country	Study Design	Time Period of the Study	Institution(s)	Study Participants		Age		P-value	Weight (kg)		P-value	PVA Z-score (Mean ± SD)		P-value	NOS Scale	
							VS	TAP	VS	TAP		VS	TAP		VS	TAP		Over-all	Risk of Bias
Included in meta-analysis (p ≤ 0.05, PVA Z-score)																			
1	**Stewart et al.**	2005	USA	Retrospective Cohort	1997-2004	Ann & Robert H. Lurie Children's Hospital of Chicago	82	20	Mean ± SD: 11 ± 8.40 months	Mean ± SD: 9.40 ± 19 months	0.7	Mean ± SD: 7.40 ± 5.80	Mean ± SD: 7.50 ± 2.80	0.9	-1.70 ± 1.20	-4.80 ± 1.70	**<0.001**	7	●
2	**Bové et al.**	2011	Belgium	Retrospective Cohort	1994-2010	University Hospital of Gent	48	47	Median: 7 months	Median: 7.50 months	0.21	-	-	-	-0.86 ± 1.15	-3.26 ± 0.95	**<0.001**	8	●
3	**Escribano et al.**	2011	Spain	Retrospective Cohort	2001-2009	Hospital Universitario 12 de Octubre	11	11	Mean ± SD: 20.90 ± 0.90 weeks		-	Mean ± SD: 2.87 ± 0.59		-	-2.30 ± 1.10	-3.30 ± 1.10	**0.041**	8	●
4	**Hua et al.**	2011	China	Retrospective Cohort	2006-2010	Fuwai Hospital and Cardiovascular Institute	132	7	Mean ± SD: 8.10 ± 3.20 months	Mean ± SD: 7.50 ± 2.10 months	-	Mean ± SD: 7.80 ± 6.20	Mean ± SD: 7.50 ± 3.70	-	-1.50 ± 1.10	-4.70 ± 1.20	**0.001**	6	●
5	**Robinson et al.**	2011	USA	Retrospective Cohort	1997-2008	Boston Children's Hospital	127	111	Mean ± SD: 93 ± 41 days	Mean ± SD: 74 ± 45 days	-	Mean ± SD: 5.04 ± 1.35	Mean ± SD: 4.56 ± 1.46	-	-2.40 ± 0.96	-2.79 ± 0.95	**<0.001**	6	●
6	**Sasson et al.**	2012	Israel	Retrospective Cohort	2003-2009	Wolfson Medical Center	69	20	Median (Range): 27 (4–192) months	Median (Range): 36 (3–226) months	0.247	Median (Range): 11.7 (4.3–49)	Median (Range): 9.35 (2.8–42.7)	0.396	0.10 ± 0.17	-3.10 ± 2.33	**<0.001**	7	●
7	**Ito et al.**	2013	Japan	Retrospective Cohort	2005-2011	Mt. Fuji Shizuoka Children's Hospital	11	8	Median (IQR): 6.9 (2.2–	Median (IQR): 8.7 (1.0–	0.65	Median (IQR):	Median (IQR):	0.68	−4.90 ± 6.89	-6.10 ± 6.85	**0.04**	7	●

No.	Study	Year	Country	Study Design	Time Period of the Study	Institution(s)	Study Participants		Age		P-value	Weight (kg)		P-value	PVA Z-score (Mean ± SD)		P-value	NOS Scale	
							VS	TAP	VS	TAP		VS	TAP		VS	TAP		Over-all	Risk of Bias
									16.1) months	13) months		6.9 (4.6 to 9.2)	6.4 (3.6 to 8.9)						
8	**Kim et al.**	2014	South Korea	Retrospective Cohort	1989-2005	Asan Medical Center	57	57	Mean ± SD: 9.3 ± 1.9 months	Mean ± SD: 9.3 ± 2.2 months	0.891	Mean ± SD: 8.2 ± 1.3	Mean ± SD: 8.3 ± 1.3	0.702	-2.00 ± 1.40	-2.90 ± 1.60	**<0.001**	9	●
9	**Vida et al.**	2014	Italy	Retrospective Cohort	2007-Unspecified	Padova University Hospital	34	35	Median (Range): 115 (36–521) days	Median (Range): 113 (65–454) days	0.41	Median (Range): 5.7 (4.6-10)	Median (Range): 6.0 (3.2-10.1)	0.92	-2.95 ± 7.58	-3.25 ± 8.48	**0.03**	7	●
10	**Choi et al.**	2016	South Korea	Retrospective Cohort	2007-2015	Pusan National University Yangsan Hospital	82	40	Mean ± SD: 10.4 ± 21.5 months	Mean ± SD: 9.6 ± 8.7 months	0.775	Mean ± SD: 7.5 ± 3.8	Mean ± SD: 7.9 ± 2.1	0.464	−0.85 ± 1.27	-2.46 ± 1.47	**<0.001**	5	●
11	**Simon et al.**	2017	USA	Retrospective Cohort	2000-2010	University of Rochester Medical Center, SUNY Upstate Medical University	42	48	Mean ± SD: 101.9 ± 60.9 days	Mean ± SD: 147.7 ± 83.2 days	**0.002**	Mean ± SD: 6.1 ± 1.7	Mean ± SD: 5.6 ± 1.8	0.17	−0.91 ± 1.56	−2.72 ± 1.35	**<0.001**	7	●
12	**Stephens et al.**	2017	USA	Retrospective Cohort	2005-2014	New York-Presbyterian Morgan Stanley Children's Hospital, Komansky Center for Children's Health	6	14	Mean ± SD: 94 ± 142 weeks	Mean ± SD: 21 ± 10 weeks	0.494	Median (IQR): 5.7 (5.1 to 6.7)	Median (IQR): 6.4 (5.3 to 7.0)	0.559	-2.0 ± 0.44	-3.10 ± 2.10	**<0.001**	7	●
13	**Hickey et al.**	2018	Canada	Retrospective Cohort	2000-2012	The Hospital for Sick Children	296	138	Median (Range):	Median (Range):	0.576	Median (Range):	Median (Range):	0.718	-4.50 ± 17.22	-6.90 ± 17.67	**<0.001**	8	●

No.	Study	Year	Country	Study Design	Time Period of the Study	Institution(s)	Study Participants		Age		P-value	Weight (kg)		P-value	PVA Z-score (Mean ± SD)		P-value	NOS Scale	
							VS	TAP	VS	TAP		VS	TAP		VS	TAP		Over-all	Risk of Bias
									182.5 (29–5527) days	171.5 (16–4235) days		6.9 (2.1–67)	6.8 (2.5–85) kg						
14	**Jiang et al.**	2020	China	Retrospective Cohort	2012-2017	Fuwai Hospital and Cardiovascular Institute	944	729	Median (Range): 320 (54–6497) days	Median (Range): 318 (57–5969) days	0.934	Mean ± SD: 10.1 ± 5.5	Mean ± SD: 10.0 ± 5.0	0.829	-1.90 ± 13.14	-2.60 ± 15.78	**<0.001**	8	●
15	**Zhao et al.**	2020	China	Retrospective Cohort	2016-2017	Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangzhou	81	156	Median (Range): 9 (6–17) months	Median (Range): 8 (6–13) months	0.173	Median (Range): 7.5 (6.5–9.0)	Median (Range): 8.0 (7.0–9.0)	0.284	−1.50 ± 1.40	−3.60 ± 1.70	**<0.001**	7	●
16	**Stephens et al.**	2021	USA	Retrospective Cohort	2008-2018	Ann & Robert H. Lurie Children's Hospital of Chicago	50	17	Median (IQR): 4.9 (2.9–5.7) months	Median (IQR): 4.5 (3.5–6.0) months	0.23	Mean ± SD: 4.7 ± 0.9	Mean ± SD: 8.0 ± 2.1	**<0.001**	0.87 ± 0.89	-1.10 ± 1.10	**<0.001**	7	●
17	**Lyu et al.**	2021	China	Retrospective Cohort	2018-2019	Beijing Anzhen Hospital, Capital Medical University	62	50	Mean ± SD: 21.01 ± 15.73 months	Mean ± SD: 25.22 ± 15.21 months	0.469	Mean ± SD: 9.54 ± 3.75	Mean ± SD: 10.45 ± 4.46	0.246	-0.43 ± 1.42	-2.24 ± 0.94	**<0.001**	6	●
18	**Kobayashi et al.**	2022	Japan	Retrospective Cohort	1991-2019	Okayama University Hospital	207	123	Median (IQR): 428	Median (IQR): 527	0.081	Median (IQR): 8.4 (7.4-9.6)	Median (IQR): 9 (7.9-10.3)	**0.018**	-1.50 ± 1.70	-3.50 ± 1.50	**<0.001**	8	●

No.	Study	Year	Country	Study Design	Time Period of the Study	Institution(s)	Study Participants		Age		P-value	Weight (kg)		P-value	PVA Z-score (Mean ± SD)		P-value	NOS Scale	
							VS	TAP	VS	TAP		VS	TAP		VS	TAP		Over-all	Risk of Bias
									(317–570) days	(331–714) days									
19	**Ono et al.**	2022	Japan	Retrospective Cohort	1978-2003	National Cerebral and Cardiovascular Center	198	242	Median (IQR): 1.6 (0.9–2.5) years	Median (IQR): 1.9 (1.3–2.7) years	**0.001**	Median (IQR): 10.4 (8.7-12.1)	Median (IQR): 9.3 (7.9-11.7)	**0.002**	0.05 ± 0.15	-1.89 ± 6.51	**<0.001**	8	●
20	**Samal et al.**	2022	India	Retrospective Cohort	2021	G.B. Pant institute of postgraduate medical education and research (GIPMER)	46	44	Mean ± SD: 14.2 ± 4.6 months	Mean ± SD: 11.5 ± 6.1 months	0.513	Mean ± SD: 8.3 ± 2.8	Mean ± SD: 7.9 ± 3.5	0.542	-0.90 ± 1.10	-3.20 ± 1.20	**0.021**	6	●
21	**Bonura et al.**	2023	USA	Retrospective Cohort	2006-2016	Saint Louis University School of Medicine	43	19	-	-	-	Mean ± SD: 6.73 ± 1.24	Mean ± SD: 6.42 ± 1.14	0.36	-1.30 ± 1.08	-2.56 ± 0.71	**<0.001**	7	●
22	**Schulte et al.**	2023	USA	Retrospective Cohort	2007-2021	Washington University School of Medicine	71	95	Median (IQR): 4.8 (3.5–6.6) months	Median (IQR): 5 (3.8–6.0) months	0.39	Median (IQR): 6 (5.3-7.0)	Median (IQR): 6.0 (4.98-7.3)	0.49	-2.00 ± 3.54	-3.70 ± 7.72	**<0.001**	6	●
23	**Minh et al.**	2024	Vietnam	Retrospective Cohort	2010-2020	Vietnam National Children's Hospital	398	134	Median (IQR): 12.0 (8.9–18) months	Median (IQR): 11.7 (8.7–16.9) months	0.66	-	-	-	-0.68 ± 3.03	-2.64 ± 6.65	**<0.001**	7	●
24	**Taksaudom et al.**	2024	Thailand	Retrospective Cohort	2006-2016	Chiang Mai University	45	88	Median (IQR): 40	Median (IQR): 41	0.708	Median (IQR): 12 (11-14.5)	Median (IQR): 12.5	0.149	-0.80 ± 1.25	-2.30 ± 5.29	**<0.001**	6	●

No.	Study	Year	Country	Study Design	Time Period of the Study	Institution(s)	Study Participants		Age		P-value	Weight (kg)		P-value	PVA Z-score (Mean ± SD)		P-value	NOS Scale	
							VS	TAP	VS	TAP		VS	TAP		VS	TAP		Over-all	Risk of Bias
									(27–56.5) months	(33–55) months			(11.2-14.5)						
25	**Mendes et al.**	2025	Switzerland	Retrospective Cohort	2019-2023	Geneva University Hospital (Humanitarian)	85	30	Median (IQR): 1487 (1052.0–2417.5) days	Median (IQR): 1022 (248.25–2287.50) days	0.032	Median (IQR): 13.00 (10.00 to 16.15)	Median (IQR): 10.65 (7.23 to 20.15)	0.076	-1.43 ± 1.46	-3.20 ± 2.37	**<0.001**	7	●
Included in meta-analysis (p > 0.05, PVA Z-score)																			
26	**Singh et al.**	2011	India	Prospective Cohort	2008	G. B. Pant Hospital	20	23	Mean (Range): 28 (6–260) months	Mean (Range): 26 (6–180) months	0.19	Mean ± SD: 10.1 ± 5.9	Mean ± SD: 10.6 ± 4.8	0.76	-2.80 ± 1.50	-3.00 ± 1.20	0.64	6	●
27	**Mandigma et al.**	2018	Philippines	Prospective Cohort	2012-2014	Philippine Heart Center	40	23	Mean ± SD: 7.0 ± 3.8 years	Mean ± SD: 7.5 ± 3.5 years	0.64	Mean ± SD: 19.5 ± 9.89	Mean ± SD: 22.5 ± 10.64	0.27	-2.10 ± 1.10	-2.50 ± 1.70	0.27	5	●
28	**Borodinova et al.**	2019	Ukraine	Prospective Cohort	2016-2017	Ukrainian Children Cardiac Center	42	16	Median (Range) 7.6 (2.1–46.3) months	Median (Range) 7.0 (0.9–41.7) months	0.37	Median (Range): 7.8 (4.2 - 15.5)	Median (Range): 6.7 (3.2 - 24.4)	0.14	-3.00 ± 1.90	-3.90 ± 2.00	0.063	7	●
29	**Wu et al.**	2021	China	Retrospective Cohort	2009-2019	The Second Xiangya Hospital of Central South University, Hunan Children's Hospital	63	65	Mean ± SD: 12.6 ± 4.8 months	Mean ± SD: 14.2 ± 6.7 months	0.113	Mean ± SD: 9.32 ± 1.63	Mean ± SD: 9.12 ± 1.16	0.423	−2.58 ± 0.30	−2.61 ± 0.26	0.502	6	●

No.	Study	Year	Country	Study Design	Time Period of the Study	Institution(s)	Study Participants		Age		P-value	Weight (kg)		P-value	PVA Z-score (Mean ± SD)		P-value	NOS Scale	
							VS	TAP	VS	TAP		VS	TAP		VS	TAP		Over-all	Risk of Bias
Included studies in review, but not included in meta-analysis (overlapping samples with other included studies)																			
30	**Sen et al.**	2016	USA	Retrospective Cohort	2010-2014	New York-Presbyterian Morgan Stanley Children's Hospital	19	32	Median (Range): 109 (5–329) days	Median (Range): 156 (6–350) days	0.279	Median (Range): 6.0 (1.9–8.5)	Median (Range): 5.6 (2.3–10.5)	0.941	-2.51 ± 5.57	-3.07 ± 9.08	0.065	6	●
31	**Hofferberth et al.**	2018	USA	Retrospective Cohort	2007-2015	Boston Children's Hospital	53	53	Mean ± SD: 96 ± 55 days	Mean ± SD: 83 ± 49 days	0.181	-	-	-	-2.21 ± 0.55	-2.26 ± 0.65	0.67	8	●
32	**Pawan et al.**	2020	India	Retrospective Cohort	2019	G. B. Pant Hospital	10	19	Mean ± SD: 18.52 ± 3.45 years	Mean ± SD: 17.28 ± 3.22 years	0.35	Mean ± SD: 35 ± 6.8	Mean ± SD: 36 ± 5.9	0.99	-1.2 ± 0.31	-2.75 ± 0.26	**0.001**	6	●
33	**Lv et al.**	2022	China	Retrospective Cohort	2014-2017	Fuwai Hospital and Cardiovascular Institute	27	27	Median (IQR): 13.0 (6.6-24.0) months	Median (IQR): 11.0 (8.0-19.0) months	0.945	Mean ± SD: 11.6 ± 9.1	Mean ± SD: 11.9 ± 9.6	0.885	−3.2 ± 1.9	−3.5 ± 0.9	0.208	7	●
34	**Borodinova et al.**	2025	Ukraine	Retrospective Cohort	Not specified	Ukrainian Children Cardiac Center	109	23	Mean ± SD: 9.03 ± 4.33 months		-	Mean ± SD: 7.6 ± 1.4		-	-3.17 ± 1.82	-4.47 ± 1.94	0.76	7	●



Studies were assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies, with a maximum possible score of 9 stars. The risk of bias was categorized as follows:

- ● Low Risk of Bias (Good Quality): 7–9 stars.
- ● Moderate Risk of Bias (Fair Quality): 5–6 stars.
- ● High Risk of Bias (Poor Quality): 0–4 stars.

3.4. Meta-Analysis Outcomes

3.4.1. Standardized Mean Difference of Z-Score between VS and TAP Group

The quantitative analysis of the preoperative standardized mean difference (SMD) Z-score was summarized in **Figure 2**, with 29 inclusion studies. These studies encompassed 5,510 patients with significant p-values across 25 studies and 296 patients from 4 studies with nonsignificant p-values. The overall findings of the me-ta-analysis demonstrated a positive SMD, with a statistically significant p-value ($p < 0.05$), indicating an increase in preoperative Z-scores associated with the use of VS RVOT reconstruction (SMD: 1.01; 95% CI: 0.75 - 1.28; $p < 0.001$; $I^2 = 95\%$). The high heterogeneity of the meta-analysis ($I^2 > 50\%$) necessitated the use of a random-effects model. In the subgroup of studies with significant p-values, the analysis also revealed a positive mean difference, a significant overall p-value, and substantial heterogeneity (SMD: 1.14; 95% CI: 0.85–1.43; $p < 0.001$; $I^2 = 95\%$).



Study or Subgroup	Valve Sparing Mean	SD	Total	Transannular Patch Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
1.1.1 Studies with Significant P value (≤0.05)									
Stewart et al., 2005	-1.7	1.2	82	-4.8	1.7	20	3.3%	2.35 [1.76, 2.94]	2005
Bove et al., 2011	-0.86	1.15	48	-3.26	0.95	47	3.4%	2.25 [1.74, 2.77]	2011
Robinson et al., 2011	-2.4	0.96	127	-2.79	0.95	111	3.8%	0.41 [0.15, 0.66]	2011
Escribano et al., 2011	-2.3	1.1	11	-3.3	1.1	11	2.7%	0.87 [-0.01, 1.76]	2011
Hua et al., 2011	1.5	1.1	132	-4.7	1.2	7	2.5%	5.58 [4.57, 6.59]	2011
Sasson et al., 2012	0.1	0.174	69	-3.1	2.3303	20	3.2%	2.88 [2.22, 3.54]	2012
Ito et al., 2013	-4.9	6.8882	11	-6.1	6.8554	8	2.7%	0.17 [-0.75, 1.08]	2013
Kim et al., 2014	-2	1.4	57	-2.9	1.6	57	3.7%	0.59 [0.22, 0.97]	2014
Vida et al., 2014	-2.95	7.5843	34	-3.25	8.4888	35	3.5%	0.04 [-0.44, 0.51]	2014
Choi et al., 2016	-0.85	1.27	82	-2.46	1.47	40	3.6%	1.20 [0.79, 1.60]	2016
Simon et al., 2017	-0.91	1.56	42	-2.72	1.35	48	3.5%	1.24 [0.78, 1.69]	2017
Stephens et al., 2017	-2	0.4383	6	-3.1	2.1041	14	2.6%	0.58 [-0.39, 1.56]	2017
Hickey et al., 2018	-4.5	17.2232	296	-6.9	17.6668	138	3.9%	0.14 [-0.06, 0.34]	2018
Jiang et al., 2020	-1.9	13.144	944	-2.6	15.7807	729	3.9%	0.05 [-0.05, 0.15]	2020
Zhao et al., 2020	-1.5	1.4	81	-3.6	1.7	156	3.8%	1.30 [1.01, 1.60]	2020
Stephens et al., 2021	0.87	0.89	50	-1.1	1.1	17	3.2%	2.06 [1.40, 2.72]	2021
Lyu et al., 2021	-0.43	1.42	62	-2.24	0.94	50	3.6%	1.46 [1.04, 1.88]	2021
Kobayashi et al., 2022	-1.5	1.7	207	-3.5	1.5	123	3.8%	1.23 [0.98, 1.47]	2022
Ono et al., 2022	0.05	0.1551	198	-1.89	6.5149	242	3.9%	0.40 [0.21, 0.59]	2022
Samal et al., 2022	-0.9	1.1	46	-3.2	1.2	44	3.4%	1.98 [1.47, 2.49]	2022
Bonura et al., 2023	-1.3	1.08	43	-2.56	0.71	19	3.3%	1.26 [0.68, 1.85]	2023
Schulte et al., 2023	-2	3.5384	71	-3.7	7.7221	95	3.8%	0.27 [-0.04, 0.58]	2023
Minh et al., 2024	-0.68	3.0316	398	-2.64	6.6531	134	3.9%	0.46 [0.26, 0.66]	2024
Taksaudom et al., 2024	-0.8	1.2544	45	-2.3	5.2899	88	3.7%	0.34 [-0.02, 0.70]	2024
Mendes et al., 2025	-1.43	1.46	85	-3.2	2.37	30	3.6%	1.01 [0.57, 1.45]	2025
Subtotal (95% CI)			**3227**			**2283**	**86.2%**	**1.14 [0.85, 1.43]**	
Heterogeneity: Tau² = 0.49; Chi² = 505.56, df = 24 (P < 0.00001); I² = 95%									
Test for overall effect: Z = 7.61 (P < 0.00001)									
1.1.2 Studies with Insignificant P value (>0.05)									
Singh et al., 2011	-2.8	1.5	20	-3	1.2	23	3.3%	0.15 [-0.45, 0.75]	2011
Mandigma et al., 2016	-2.1	1.1	40	-2.5	1.7	27	3.5%	0.29 [-0.20, 0.78]	2016
Borodinova et al., 2019	-3	1.9	42	-3.9	2	16	3.3%	0.46 [-0.12, 1.04]	2019
Wu et al., 2021	-2.58	0.3	63	-2.61	0.26	65	3.7%	0.11 [-0.24, 0.45]	2021
Subtotal (95% CI)			**165**			**131**	**13.8%**	**0.21 [-0.02, 0.45]**	
Heterogeneity: Tau² = 0.00; Chi² = 1.20, df = 3 (P = 0.75); I² = 0%									
Test for overall effect: Z = 1.77 (P = 0.08)									
Total (95% CI)			**3392**			**2414**	**100.0%**	**1.01 [0.75, 1.28]**	
Heterogeneity: Tau² = 0.46; Chi² = 512.80, df = 28 (P < 0.00001); I² = 95%									
Test for overall effect: Z = 7.52 (P < 0.00001)									
Test for subgroup differences: Chi² = 23.45, df = 1 (P < 0.00001), I² = 95.7%									

Figure 2. Forest plot illustrating the meta-analysis of preoperative Z-score mean differences stratified by the type of RVOT reconstruction.

3.4.2. Preoperative Grand Mean of Z-Score in VS Group

This meta-analysis also evaluated the grand mean of the preoperative Z-score in the VS group, based on data from 29 studies, as illustrated in **Figure 3 (a).** The

grand mean preoperative Z-score, calculated from 3,392 patients in the VS group, was -1.39 (95% CI: -1.79 to -0.98; $p < 0.001$; $I^2 = 100\%$). These results are statistically significant, as indicated by a p-value < 0.05. Due to the heterogeneity of this analysis, a ran-dom-effects model was employed to calculate the grand mean.

3.4.3. Preoperative Grand Mean of Z-Score in TAP Group

The grand mean of preoperative Z-scores in the TAP group, derived from 29 studies, is presented in **Figure 3 (b).** Among 2,414 patients in this group, the grand mean preoperative Z-score was -2.97 (95% CI: -3.20 to -2.75; $p < 0.001$; $I^2 = 88\%$). This result is statistically significant, with a p-value < 0.05. Due to the heterogeneity of the total analysis, instead of low heterogeneity in subgroup analysis ($I^2 = 0\%$), a random-effects model was applied to calculate the grand mean in this meta-analysis.



Figure 3. Forest plot graphics of preoperative grand mean Z-score in: **(a)** Patients undergoing valve-sparing technique; **(b)** Patients undergoing transannular patch technique.

3.4.4. Preoperative Z-score Cut-Off Assessment for VS

An analysis was performed using the receiver operating characteristic (ROC) curve based on preoperative Z-score data from 29 included studies to determine the optimal Z-score cut-off for valve-sparing procedures, as shown in **Figure 4 (a).** The ROC analysis demonstrated an area under the curve (AUC) value of 0.85 (>0.80;

95% CI, 0.84 – 0.86), indicating excellent discriminatory ability of the preoperative Z-score, with statistically significant results ($p < 0.001$).

The determination of the optimal Z-score cut-off values was based on identifying the best sensitivity and specificity at various points on the curve (> 80%). Three rec-ommended Z-score cut-offs for guiding valve-sparing procedures were identified: Z-score ≥ -2.59 (sensitivity 88%, specificity 80%), Z-score ≥ -2.43 (sensitivity 86%, spec-ificity 84%), and Z-score ≥ -2.17 (sensitivity 82%, specificity 89%). The detailed analysis of these cut-off points is presented in **Figure 4 (b).**



(a) (b)

Figure 4. Preoperative Z-score cut off evaluation: **(a)** ROC curve analysis; **(b)** Sensitivity and specificity graphic for determining the optimal cut-off point.

4. Discussion

This systematic review and meta-analysis of 29 studies involving 5,806 patients demonstrates that the preoperative PVA z-score is a critical predictor for the feasibility of VS repair in ToF. Our analysis revealed a significantly higher preoperative PVA z-score in patients who underwent VS repair compared to those requiring a TAP (SMD: 1.01). Furthermore, we identified several suggestive diagnostic thresholds, for optimizing successful valve preservation. These findings provide a quantitative evi-dence base to guide surgical decision-making for VS techniques. The robustness of our data synthesis was confirmed by the absence of significant publication bias. Visual inspection of the funnel plot (Figure A1) showed

a symmetrical distribution of studies, statistically supported by Egger's test (p = 0.88). This indicates that the pooled results are not skewed by small-study effects. Therefore, recent surgical advancements have emphasized VS techniques aimed at preserving pulmonary valve function, minimizing pulmonary regurgitation (PR), and enhancing long-term survival and quality of life. [21,26,41]

The PVA size is a critical determinant in selecting the appropriate RVOT reconstruction strategy for patients with ToF. Patients with a markedly small PVA typically require TAP repair, whereas those with a sufficiently large PVA are more suitable candidates for VS approaches. However, for patients with intermediate PVA sizes, the choice of RVOT reconstruction method often depends on the surgeon's expertise, preferences, or institutional practices, highlighting variability in clinical decision-making, without any standardized cut-off. [5,10,22]

This meta-analysis, coupled with ROC curve analysis of the preoperative PVA z-score, aims to provide insights into long-term outcomes, spanning over 20 years, across a large, global cohort of patients who have undergone either TAP or VS RVOT reconstruction strategies. This comprehensive approach allows for a more robust un-derstanding of the long-term effects of these surgical methods. In this meta-analysis, the SMD in PVA Z-scores between patient groups undergoing RVOT reconstruction with VS and TAP was positive. This result was observed both across all studies and within studies with statistically significant p-values. These findings suggest that higher preoperative Z-score values are associated with a greater likelihood of employing VS techniques. [5,11,28,31]

This meta-analysis also included a grand mean z-score assessment across 29 studies comparing VS and TAP groups. The pooled grand mean PVA z-scores were -1.48 for the VS group and -2.93 for the TAP group. The higher grand mean z-score ob-served in the VS group aligns with the results of the mean difference analysis, supporting the association between larger PVA z-scores and the feasibility of VS proce-dures. [23,25,27]

While VS repair for ToF could help protect the right ventricle from volume over-load, the potential for residual obstruction remains a concern. The application of PVA Z-score cut-off is remain inconsistent across countries, as reflected in the variability of reported median z-scores, with conflicting evidences in the literature.

Some studies suggest a PVA z-score of -2 as a threshold for TAP. [42] Meanwhile others, such as Stewart et al., found that a PVA z-score greater than -4 predicted successful pulmo-nary valve preservation with minimal recurrent obstruction. [15] Conversely, a Japa-nese study reported that even in patients with PVA z-scores below -4 (ranging from -6.3 to -4.3), valve-sparing surgery was successful in 58% of cases. [21] Furthermore, other studies indicate that valve-sparing techniques can be effectively performed in patients with PVA z-scores as low as -2.5, without increasing the risk for residual RVOT obstruction, compared to TAP. [3]

This study proposes three optimal cut-off values with the highest sensitivity and specificity for discrimination. The receiver operating characteristic (ROC) curve anal-ysis demonstrated significant results, indicating an excellent discriminatory ability of the PVA z-score. The recommended cut-off values are as follows: z-score ≥ -2.59 (sensi-tivity 88%, specificity 80%), z-score ≥ -2.43 (sensitivity 86%, specificity 84%), and z-score ≥ -2.17 (sensitivity 82%, specificity 89%). Among these, the z-score ≥ -2.59 is preferred due to its higher sensitivity, enhancing the optimization of VS reconstruc-tion. This recommendation aligns with recent studies emphasizing the benefits of maximizing VS techniques over TAP due to minimizing complications of TAP such as severe pulmonary insuficiency, cardiac arrhythmia, right ventricular dilatation, even sudden cardiac death. [9,21,22,36,37]

This meta-analysis has several limitations. First, the reliance on observational cohort studies introduces inherent selection bias, as surgical decisions were driven by intraoperative assessment rather than randomization. Second, high statistical hetero-geneity (I2 > 50%) was observed, reflecting global variations in surgical techniques and patient demographics. Third, the pooled z-score results might be significantly influ-enced by methodological heterogeneity, as z-score values vary depending on the spe-cific allometric method applied by each institution. Finally, while this study establishes the z-score as a feasibility predictor, it does not directly meta-analyze long-term functional outcomes such as right ventricular remodeling.

5. Conclusion

In conclusion, this meta-analysis demonstrates that VS repair is a viable alternative strongly associated with larger preoperative PVA z-scores. While TAP repair effectively relieves stenosis in Tetralogy of Fallot, it is associated with significant long-term pulmonary regurgitation. This meta-analysis identified an optimal z-score threshold of ≥ -2.59, offering reliable guidance for surgical decision-making with high diagnostic accuracy. Adopting this quantitative criterion allows for more precise sur-gical planning, promoting the broader use of valve-preservation strategies to minimize long-term complications and to improve patient survival.

Author Contributions: Conceptualization, D.F., J.S., and S.P.; methodology, D.F. and J.S. ; soft-ware, J.S.; validation, D.F., S.P., P.B., and B.R.; formal analysis, J.S., N.V.; investigation, D.F., J.S., P.U., L.H.; resources, M.D., D.P.; data curation, J.S.; writing - original draft preparation, J.S.; writing - review and editing, D.F., J.S.; visualization, J.S., S.P.; supervision, P.B., B.R., M.D.; project administration, S.P., P.B.; funding acquisition, D.F. All authors have read and agreed to the pub-lished version of the manuscript.

Funding: This research received no specific grant from any funding agency.

Conflicts of Interest: The authors have no conflicts of interests to disclose in relation to this meta-analysis and systematic review.

Abbreviations

The following abbreviations are used in this manuscript:

AUC	Area Under the Curve
CHD	Congenital Heart Disease
CI	Confidence Interval
IQR	Interquartile Range
MD	Mean Difference
NOS	Newcastle-Ottawa Scale
PICO	Patient, Intervention, Comparison, Outcome
PR	Pulmonary Regurgitation
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PS	Pulmonary Stenosis
PVA	Pulmonary Valve Annulus
RevMan	Review Manager
ROC	Receiver Operating Characteristic
RVOT	Right Ventricular Outflow Tract
SD	Standard Deviation
SMD	Standardized Mean Difference
SPSS	Statistical Package for the Social Sciences
TAP	Transannular Patch
ToF	Tetralogy of Fallot
VS	Valve-Sparing

Appendix

Table A1. Quality assessment of included studies using Newcastle-Ottawa Scale

No.	Study and year	Selection				Comparability		Outcome			Overall	Risk of bias
		Representation of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Outcome not present at the start	Main factor	Additional factor	Assessment of outcome	Sufficiency of follow-up time	Adequacy of follow-up		
1	Stewart *et al.*, 2005	★	★	★	★	★	-	★	★	-	7	●
2	Bové *et al.*, 2011	★	★	★	★	★	-	★	★	★	8	●
3	Escribano *et al.*, 2011	★	★	★	★	★	-	★	★	★	8	●
4	Hua *et al.*, 2011	★	★	★	★	-	-	★	★	-	6	●
5	Robinson *et al.*, 2011	★	★	★	★	-	-	★	★	-	6	●
6	Sasson *et al.*, 2012	★	★	★	★	★	-	★	★	-	7	●
7	Ito *et al.*, 2013	★	★	★	★	-	-	★	★	★	7	●
8	Kim *et al.*, 2014	★	★	★	★	★	★	★	★	★	9	●
9	Vida *et al.*, 2014	★	★	★	★	-	-	★	★	★	7	●
10	Choi *et al.*, 2016	★	★	★	★	-	-	★	-	-	5	●
11	Simon *et al.*, 2017	★	★	★	★	-	-	★	★	★	7	●
12	Stephens *et al.*, 2017	★	★	★	★	-	-	★	★	★	7	●
13	Hickey *et al.*, 2018	★	★	★	★	★	-	★	★	★	8	●
14	Jiang *et al.*, 2020	★	★	★	★	★	★	★	★	-	8	●
15	Zhao *et al.*, 2020	★	★	★	★	-	-	★	★	★	7	●
16	Stephens *et al.*, 2021	★	★	★	★	★	-	★	★	-	7	●
17	Lyu *et al.*, 2021	★	★	★	★	-	-	★	-	★	6	●
18	Kobayashi *et al.*, 2022	★	★	★	★	★	-	★	★	★	8	●
19	Ono *et al.*, 2022	★	★	★	★	★	★	★	★	-	8	●
20	Samal *et al.*, 2022	★	★	★	★	-	-	★	-	★	6	●

21	Bonura *et al.*, 2023	★	★	★	★	★	-	★	★	-	7	●
22	Schulte *et al.*, 2023	★	★	★	★	-	-	★	★	-	6	●
23	Minh *et al.*, 2024	★	★	★	★	-	-	★	★	★	7	●
24	Taksaudom *et al.*, 2024	★	★	★	★	-	-	★	★	-	6	●
25	Mendes *et al.*, 2025	★	★	★	★	★	★	★	-	-	7	●
26	Singh *et al.*, 2011	★	★	★	★	-	-	★	-	★	6	●
27	Mandigma *et al.*, 2016	★	★	-	★	-	-	★	-	★	5	●
28	Borodinova *et al.*, 2019	★	★	★	★	★	-	★	★	-	7	●
29	Wu *et al.*, 2021	★	★	★	★	-	-	★	★	-	6	●
30	Sen *et al.*, 2016	★	★	★	★	-	-	★	★	-	6	●
31	Hofferberth *et al.*, 2017	★	★	★	★	★	★	★	★	-	8	●
32	Pawan *et al.*, 2020	★	★	★	★	-	-	★	-	★	6	●
33	Lv *et al.*, 2022	★	★	★	★	★	-	★	★	-	7	●
34	Borodinova *et al.*, 2025	★	★	★	★	-	-	★	★	★	7	●



Studies were assessed using the **Newcastle-Ottawa Scale (NOS)** for cohort studies, with a maximum possible score of 9 stars. The risk of bias was categorized as follows:

- ● **Low Risk of Bias (Good Quality):** 7–9 stars.
- ● **Moderate Risk of Bias (Fair Quality):** 5–6 stars.
- ● **High Risk of Bias (Poor Quality):** 0–4 stars.



Figure A1. Funnel plot for preoperative PVA z-scores showing symmetrical distribution, confirming the absence of significant publication bias (Egger's test p = 0.88).

References

1. van der Ven JPG, van den Bosch E, Bogers AJCC, Helbing WA. Current outcomes and treatment of tetralogy of Fallot. F1000Res. 2019 Aug 29;8:F1000 Faculty Rev-1530.
2. Vanderlaan RD, Barron DJ. Optimal Surgical Management of Tetralogy of Fallot. CJC Pediatr Congenit Heart Dis. 2023 Sept 13;2(6Part A):352–60.
3. Hofferberth SC, Nathan M, Marx GR, Lu M, Sleeper LA, Marshall AC, et al. Valve-sparing repair with intraoperative balloon dilation in tetralogy of Fallot: Midterm results and therapeutic implications. The Journal of Thoracic and Cardiovascular Surgery. 2018 Mar;155(3):1163-1173.e4.
4. Martins IF, Doles IC, Bravo-Valenzuela NJM, dos Santos AOR, Varella MSP. When is the Best Time for Corrective Surgery in Patients with Tetralogy of Fallot between 0 and 12 Months of Age? Braz J Cardiovasc Surg. 2018;33(5):505–10.
5. Kim GS, Han S, Yun TJ. Pulmonary Annulus Preservation Lowers the Risk of Late Postoperative Pulmonary Valve Implantation After the Repair of Tetralogy of Fallot. Pediatr Cardiol. 2014;36(2):402–8.

6. Kwon MH, Bacha EA. Pulmonary Valve-Sparing Techniques for Tetralogy of Fallot: A Systematic Approach for Maximizing Success and Minimizing Risk. Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual. 2020 Jan 1;23:24–8.
7. Jiang X, Liu J, Peng B, Zhang H, Li S, Yan J, et al. Impact of Annulus-Sparing on Surgical Adequacy of Pulmonary Valve in Complete Repair of Tetralogy of Fallot with Right Ventricular Outflow Tract Incision. Pediatr Cardiol. 2020;42(2):379–88.
8. Lv L, Liu J, Jiang X, Liu Y, Tian Y, Cao H, et al. Feasibility and Surgical Effect of Annulus Sparing in Consecutive Patients with Tetralogy of Fallot: A Retrospective Cohort Study. Cardiology Discovery. 2022 Dec;2(4):218–25.
9. Lyu Z, Jin M, Yang Y. Value of pulmonary annulus index in predicting transannular patch in tetralogy of Fallot repair. Journal of Cardiac Surgery. 2021 July;36(7):2197–203.
10. Samal S, Sharma R, Minhas HS, G G, Agarwal S, Naqvi SEH, et al. Role of great artery annulus ratio to predict transannular patch enlargement in repair of tetralogy of Fallot. Cardiothorac Surg. 2022 Sept 13;30(1):25.
11. Vida VL, Guariento A, Castaldi B, Sambugaro M, Padalino MA, Milanesi O, et al. Evolving strategies for preserving the pulmonary valve during early repair of tetralogy of Fallot: Mid-term results. The Journal of Thoracic and Cardiovascular Surgery. 2014 Feb;147(2):687–96.
12. Zhao J, Cai X, Teng Y, Nie Z, Ou Y, Zhuang J, et al. Value of pulmonary annulus area index in predicting transannular patch placement in tetralogy of Fallot repair. J Card Surg. 2020 Jan;35(1):48–53.
13. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014 Dec 19;14:135.
14. Hariyanto TI, Japar KV, Kwenandar F, Damay V, Siregar JI, Lugito NPH, et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: A systematic review and meta-analysis. The American Journal of Emergency Medicine. 2021 Mar 1;41:110–9.

15. Stewart RD, Backer CL, Young L, Mavroudis C. Tetralogy of Fallot: Results of a Pulmonary Valve-Sparing Strategy. The Annals of Thoracic Surgery. 2005 Oct;80(4):1431–9.
16. Bové T, François K, Van De Kerckhove K, Panzer J, De Groote K, De Wolf D, et al. Assessment of a right-ventricular infundibulum-sparing approach in transatrial–transpulmonary repair of tetralogy of Fallot. Eur J Cardiothorac Surg. 2012 Jan;41(1):126–33.
17. Escribano D, Herraiz I, Granados Ma, Arbues J, Mendoza A, Galindo A. Tetralogy of Fallot: prediction of outcome in the mid-second trimester of pregnancy. Prenatal Diagnosis. 2011 Dec;31(12):1126–33.
18. Hua Z, Li S, Wang L, Hu S, Wang D. A new pulmonary valve cusp plasty technique markedly decreases transannular patch rate and improves midterm outcomes of tetralogy of Fallot repair. European Journal of Cardio-Thoracic Surgery. 2011 Mar;S101079401100234X.
19. Robinson JD, Rathod RH, Brown DW, Del Nido PJ, Lock JE, McElhinney DB, et al. The evolving role of intraoperative balloon pulmonary valvuloplasty in valve-sparing repair of tetralogy of Fallot. The Journal of Thoracic and Cardiovascular Surgery. 2011 Dec;142(6):1367–73.
20. Sasson L, Houri S, Raucher Sternfeld A, Cohen I, Lenczner O, Bove EL, et al. Right ventricular outflow tract strategies for repair of tetralogy of Fallot: effect of monocusp valve reconstruction. European Journal of Cardio-Thoracic Surgery. 2013 Apr;43(4):743–51.
21. Ito H, Ota N, Murata M, Tosaka Y, Ide Y, Tachi M, et al. Technical modification enabling pulmonary valve-sparing repair of a severely hypoplastic pulmonary annulus in patients with tetralogy of Fallot†. Interactive CardioVascular and Thoracic Surgery. 2013 June;16(6):802–7.
22. Choi KH, Sung SC, Kim H, Lee HD, Ban GH, Kim G, et al. A Novel Predictive Value for the Transannular Patch Enlargement in Repair of Tetralogy of Fallot. The Annals of Thoracic Surgery. 2016 Feb;101(2):703–7.
23. Simon BV, Swartz MF, Egan M, Cholette JM, Gensini F, Alfieris GM. Use of a Dacron Annular Sparing Versus Limited Transannular Patch With

Nominal Pulmonary Annular Expansion in Infants With Tetralogy of Fallot. The Annals of Thoracic Surgery. 2017 Jan;103(1):186–92.

24. Stephens EH, Tingo J, Najjar M, Yilmaz B, Levasseur S, Dayton JD, et al. Cardiac Function After Tetralogy of Fallot/Complete Atrioventricular Canal Repair. World J Pediatr Congenit Heart Surg. 2017 Mar;8(2):189–95.
25. Hickey E, Pham-Hung E, Halvorsen F, Gritti M, Duong A, Wilder T, et al. Annulus-Sparing Tetralogy of Fallot Repair: Low Risk and Benefits to Right Ventricular Geometry. The Annals of Thoracic Surgery. 2018 Sept;106(3):822–9.
26. Stephens EH, Wolfe BL, Talwar AA, Patel A, Camarda JA, Eltayeb O, et al. Applicability and Durability of Valve-Sparing Tetralogy of Fallot Repair. World J Pediatr Congenit Heart Surg. 2021 Sept;12(5):628–34.
27. Kobayashi Y, Kotani Y, Kuroko Y, Kawabata T, Sano S, Kasahara S. Staged Repair of Tetralogy of Fallot: A Strategy for Optimizing Clinical and Functional Outcomes. The Annals of Thoracic Surgery. 2022 May;113(5):1575–81.
28. Ono Y, Hoashi T, Imai K, Okuda N, Komori M, Kurosaki K, et al. Impact of right ventriculotomy for tetralogy of Fallot repair with a pulmonary valve–sparing procedure. JTCVS Open. 2022 Mar;9:191–205.
29. Bonura ED, Zhang Z, Peterson R. Incidence of branch pulmonary artery stenosis requiring intervention based on surgical repair type for tetralogy of Fallot. Progress in Pediatric Cardiology. 2023 Mar;68:101606.
30. Schulte LJ, Miller PC, Bhat AN, Carvajal-Dominguez HG, Chomat MR, Miller JR, et al. Evolution of Pulmonary Valve Management During Repair of Tetralogy of Fallot: A 14-year Experience. The Annals of Thoracic Surgery. 2023 Feb;115(2):462–9.
31. Minh DT, Huu UN, Tuan BL, Tuan MN, Dinh DM, Quang VT, et al. Effectiveness of pulmonary valve-sparing strategy for transatrial-transpulmonary repair of tetralogy of Fallot: a single institution experience. Cardiol Young. 2024 Aug;34(8):1662–9.
32. Taksaudom N, Thuropathum P, Tepsuwan T, Tantraworasin A, Sittiwangkul R, Phothikun A, et al. Comparison of Right Ventricular Outflow Tract

Reconstruction Techniques on Mid-Term Pulmonic Valve Fate. World J Pediatr Congenit Heart Surg. 2024 July;15(4):481–7.

33. Mendes V, Mouloudi A, Jolou J, Nalecz T, Abecasis A, Pereira T, et al. Predictors of successful pulmonary valve-sparing repair in pediatric humanitarian patients with Tetralogy of Fallot. J Cardiothorac Surg. 2025 May 28;20(1):243.
34. Singh S, Pratap H, Agarwal S, Singh A, Satsangi DK. Pulmonary valve preservation in Tetralogy of Fallot with a mildly hypoplastic annulus-should we do it? Indian J Thorac Cardiovasc Surg. 2011 June 1;27(2):76–82.
35. Mandigma LG. CongenitalCardiology. 2018 [cited 2026 Jan 22]. Surgical Outcomes in Pediatric Patients, Who Underwent Tetralogy of Fallot Correction. Available from: https://www.congenitalcardiologytoday.com/post/surgical-outcomes-in-pediatric-patients-who-underwent-tetralogy-of-fallot-correction-relative-to-d
36. Borodinova O, Mykychak Y, Yemets I. Transesophageal Echocardiographic Predictor of Significant Right Ventricular Outflow Tract Obstruction After Tetralogy of Fallot Repair. Seminars in Thoracic and Cardiovascular Surgery. 2020;32(2):282–9.
37. Wu M, Fan C, Liu J, Iroegbu CD, Chen W, Huang P, et al. Clinical Application of Individualized Pulmonary Bi-Orifice for the Reconstruction of Right Ventricular Outflow Tract in Tetralogy of Fallot. Front Cardiovasc Med. 2021 Nov 26;8:772198.
38. Sen DG, Najjar M, Yimaz B, Levasseur SM, Kalessan B, Quaegebeur JM, et al. Aiming to Preserve Pulmonary Valve Function in Tetralogy of Fallot Repair: Comparing a New Approach to Traditional Management. Pediatr Cardiol. 2016 June;37(5):818–25.
39. Pawan S, Agarwal P, Saha D. Effect of transannular patching on right ventricular function as compared to non transannular patch during early postoperative recovery in repair of adult tetralogy of fallot. . P. 9(2).
40. Borodinova OS, Mykhailovska AO. Long-Term Outcomes of Tetralogy of Fallot Repair with Pulmonary Valve Preservation and with Transannular Patch. ujcvs. 2025 Sept 25;33(3):49–56.

41. Yi K, Wang D, Xu J, Zhang X, Wang W, Gao J, et al. Surgical Strategies for Preservation of Pulmonary Valve Function in a Radical Operation for Tetralogy of Fallot: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022;9:888258.
42. Awori MN, Mehta NP, Mitema FO, Kebba N. Optimal Use of Z-Scores to Preserve the Pulmonary Valve Annulus During Repair of Tetralogy of Fallot. World J Pediatr Congenit Heart Surg. 2018 May;9(3):285–8.


Identification of studies via databases and registers
Identification of studies via other methods
Identification
Screening
Included


Wound Sparing
Transanastomotic Patch
Std. Mean Difference
Study or Subgroup
Mean
SD
Total
Mean
SD
Total
Weight
IV, Random, 95% CI
Year
Std. Mean Difference
IV, Random, 95% CI
Total (95% CI)
Wound Sparing
Transanastomotic Patch


Grand Mean
Study or Subgroup
Grand Mean
SD
Weight
M. Random, 95 % CI
Year
Grand Mean
M. Random, 95 % CI
2.1.1 Studies with Significant P value (<0.05)
Subtotal (95% CI)
2.1.2 Studies with Nonsignificant P value (>0.05)
Subtotal (95% CI)
Total (95 % CI)
Lascore experimental
Lascore control


Grand Mean
Grand Mean
Study or Subgroup
Grand Mean
SD
Weight
M. Random, 95 % CI
Year
M. Random, 95 % CI
3.1.1 Studies with Significant P Value (<0.05)
Subtotal (95% CI)
3.1.2 Studies with Nonsignificant P value (>0.05)
Subtotal (95% CI)
Total (95 % CI)
Lascore experimental
Lascore control



Diagonal segments are produced by ties.


$Z^{25th} > -2.59$
Sn = 0.88
Sp = 0.80
$Z^{29th} > -2.43$
Sn = 0.86
Sp = 0.84
$Z^{32nd} > -2.17$
Sn = 0.82
Sp = 0.89
Value
1.000
0.800
0.600
0.400
0.200
0.000
Sensitivity
Specificity
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49
Cut-off Point
Sensitivity (Sn)
Specificity (Sp)